Page 264 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 14 Cancer Immunotherapy 243

thus finding ways to incorporate immunotherapy into current 17. Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L,
standard of care may actually enhance the effectiveness of these Marabelle A: Rationale for anti-OX40 cancer immunotherapy, Eur
J Cancer 52:50–66, 2016.
modalities. For example, we have observed that the use of lipo-
VetBooks.ir somal clodronate therapy to eliminate MDSCs can enhance the 18. Knee DA, Hewes B, Brogdon JL: Rationale for anti-GITR cancer
immunotherapy, Eur J Cancer 67:1–10, 2016.
tumor response to chemotherapy in dogs with malignant his-
tiocytosis. 262 We hypothesize that the immunosuppressive cells 19. Henick BS, Herbst RS, Goldberg SB: The PD-1 pathway as a ther-
apeutic target to overcome immune escape mechanisms in cancer,
present in the tumor microenvironment are capable of protect- Expert Opin Ther Targets 18(12):1407–1420, 2014.
ing tumor cells from the effects of chemotherapy, thus by remov- 20. McDermott DF, Atkins MB: PD-1 as a potential target in cancer
ing these tumor cells, we can enhance the effectiveness of the therapy, Cancer Med 2(5):662–673, 2013.
chemotherapy. We predict that the use of immunotherapy as 21. Shi F, Shi M, Zeng Z, et al.: PD-1 and PD-L1 upregulation pro-
part of a protocol to treat canine and feline diseases should soon motes CD8(+) T-cell apoptosis and postoperative recurrence in hepa-
become routine. By understanding the role of the immune sys- tocellular carcinoma patients, Int J Cancer 128(4):887–896, 2011.
tem in cancer in our small animal patients, we can develop better 22. Mu CY, Huang JA, Chen Y, et al.: High expression of PD-L1 in
immunotherapies that will not only benefit these patients, but lung cancer may contribute to poor prognosis and tumor cells
also ones that will be applicable to human medicine. immune escape through suppressing tumor infiltrating dendritic
cells maturation, Med Oncol 28(3):682–688, 2011.
23. Nomi T, Sho M, Akahori T, et al.: Clinical significance and thera-
References peutic potential of the programmed death-1 ligand/programmed
death-1 pathway in human pancreatic cancer, Clin Cancer Res
1. Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, 13(7):2151–2157, 2007.
Melero I: Orchestrating immune check-point blockade for cancer 24. Hartley G, Faulhaber E, Caldwell A, et al.: Immune regulation
immunotherapy in combinations, Curr Opin Immunol 27:89–97, of canine tumour and macrophage PD-L1 expression, Vet Comp
2014. Oncol 15(2):534–549, 2017.
2. Quezada SA, Peggs KS: Exploiting CTLA-4, PD-1 and PD-L1 to 25. Brahmer JR, Tykodi SS, Chow LQ, et al.: Safety and activity of
reactivate the host immune response against cancer, Br J Cancer anti-PD-L1 antibody in patients with advanced cancer, N Engl J
108(8):1560–1565, 2013. Med 366(26):2455–2465, 2012.
3. Topalian SL, Drake CG, Pardoll DM: Immune checkpoint block- 26. Coy J, Caldwell A, Chow L, et al.: PD-1 expression by canine T
ade: a common denominator approach to cancer therapy, Cancer cells and functional effects of PD-1 blockade, Vet Comp Oncol
Cell 27(4):450–461, 2015. 15(4):1487–1502, 2017.
4. Wu YL, Liang J, Zhang W, Tanaka Y, Sugiyama H: Immunothera- 27. Maekawa N, Konnai S, Takagi S, et al.: A canine chimeric mono-
pies: the blockade of inhibitory signals, Int J Biol Sci 8(10):1420– clonal antibody targeting PD-L1 and its clinical efficacy in canine
1430, 2012. oral malignant melanoma or undifferentiated sarcoma, Scientific
5. Venur VA, Joshi M, Nepple KG, Zakharia Y: Spotlight on reports 7(1):8951, 2017.
nivolumab in the treatment of renal cell carcinoma: design, devel- 28. Jin D, Fan J, Wang L, et al.: CD73 on tumor cells impairs anti-
opment, and place in therapy, Drug Des Devel Ther 11:1175–1182, tumor T-cell responses: a novel mechanism of tumor-induced
2017. immune suppression, Cancer Res 70(6):2245–2255, 2010.
6. Burnet M: Cancer; a biological approach. I. The processes of con- 29. Holmgaard RB, Zamarin D, Munn DH, et al.: Indoleamine
trol, Br Med J 1(5022):779–786, 1957. 2,3-dioxygenase is a critical resistance mechanism in antitumor T
7. Stutman O: Tumor development after 3-methylcholanthrene cell immunotherapy targeting CTLA-4, J Exp Med 210(7):1389–
in immunologically deficient athymic-nude mice, Science 1402, 2013.
183(124):534–536, 1974. 30. Platten M, von Knebel Doeberitz N, Oezen I, et al.: Cancer
8. Rygaard J, Povlsen CO: The mouse mutant nude does not develop Immunotherapy by Targeting IDO1/TDO and Their Downstream
spontaneous tumours. An argument against immunological surveil- Effectors, Front Immunol 5:673, 2014.
lance, Acta Pathol Microbiol Scand B Microbiol Immunol 82(1):99– 31. Reinis M. Immunotherapy of MHC class I-deficient tumors.
106, 1974. Future oncology 6(10):1577–1589
9. Schreiber TH, Podack ER: A critical analysis of the tumour immu- 32. Garrido F, Algarra I, Garcia-Lora AM: The escape of cancer from
nosurveillance controversy for 3-MCA-induced sarcomas, Br J T lymphocytes: immunoselection of MHC class I loss variants har-
Cancer 101(3):381–386, 2009. boring structural-irreversible “hard” lesions, Cancer immunology,
10. Rabinovich GA, Gabrilovich D, Sotomayor EM: Immunosuppres- immunotherapy : CII 59(10):1601–1606, 2010.
sive strategies that are mediated by tumor cells, Annu Rev Immunol 33. Rimsza LM, Farinha P, Fuchs DA, et al.: HLA-DR protein sta-
25:267–296, 2007. tus predicts survival in patients with diffuse large B-cell lym-
11. Dolan DE, Gupta S: PD-1 pathway inhibitors: changing the land- phoma treated on the MACOP-B chemotherapy regimen, Leuk
scape of cancer immunotherapy, Cancer Control 21(3):231–237, Lymphoma 48(3):542–546, 2007.
2014. 34. Rimsza LM, Roberts RA, Miller TP, et al.: Loss of MHC class II
12. Jin HT, Ahmed R, Okazaki T: Role of PD-1 in regulating T-cell gene and protein expression in diffuse large B-cell lymphoma is
immunity, Curr Top Microbiol Immunol 350:17–37, 2011. related to decreased tumor immunosurveillance and poor patient
13. Lonberg N, Korman AJ: Masterful antibodies: checkpoint block- survival regardless of other prognostic factors: a follow-up study
ade, Cancer Immunol Res 5(4):275–281, 2017. from the Leukemia and Lymphoma Molecular Profiling Project,
14. Robert C, Soria JC, Eggermont AM: Drug of the year: programmed Blood 103(11):4251–4258, 2004.
death-1 receptor/programmed death-1 ligand-1 receptor monoclo- 35. Rao S, Lana S, Eickhoff J, et al.: Class II MHC expression predicts
nal antibodies, Eur J Cancer 49(14):2968–2971, 2013. survival in canine B cell lymphoma, J Vet Intern Med 25(5):1097–
15. Webb ES, Liu P, Baleeiro R, Lemoine NR, Yuan M, Wang YH: 1105, 2011.
Immune checkpoint inhibitors in cancer therapy, J Biomed Res ePub 36. Kusmartsev S, Gabrilovich DI: Immature myeloid cells and can-
ahead of print, 2017. cer-associated immune suppression, Cancer Immunol Immunother
16. Linch SN, McNamara MJ, Redmond WL: OX40 Agonists and 51(6):293–298, 2002.
Combination Immunotherapy: putting the Pedal to the Metal, 37. Yang L, DeBusk LM, Fukuda K, et al.: Expansion of myeloid
Front Oncol 5:34, 2015. immune suppressor Gr+CD11b+ cells in tumor-bearing host